Highlights in relapsing-remitting multiple sclerosis from ECTRIMS 2024 include treatment for pediatric-onset MS, safety of frexalimab, pregnancy-related considerations, and efficacy of tolebrutinib.
Older cancer survivors who had overweight or obesity at the time of first diagnosis had a higher risk for second cancers, particularly obesity-related cancers.
CAR T-cell therapy offers the "holy grail" of precision therapy in lung cancer, but it is biologically challenging and poses significant problems, according to experts.